Uterine Artery Embolization Improves Quality of Life in Patients with Pure Adenomyosis: A Single‑Center Experience
| Autor: | Hayat Matouk Alharthy, Fares Garad, Sultan Alammari, Abdulwaeed Alruhaimi, Hatim Alobaidi, Ibrahim Alrashidi, Abdulrahman Alkhalifah, Abdulaziz Almathami, Faisal Alahmari |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Hysterectomy business.industry Uterine fibroids medicine.medical_treatment R895-920 uterine artery embolization Single Center medicine.disease Surgery Medical physics. Medical radiology. Nuclear medicine Uterine artery embolization Quality of life adenomyosis menorrhagia medicine Amenorrhea Adenomyosis medicine.symptom Prospective cohort study business dysmenorrhea and uterine fibroid symptom and health-related quality of life |
| Zdroj: | The Arab Journal of Interventional Radiology, Vol 4, Iss 02, Pp 117-120 (2020) |
| ISSN: | 2542-7083 2542-7075 |
| Popis: | Aim: The aim of the study was to assess clinical outcomes following uterine artery embolization (UAE) in the treatment of dysmenorrhea and menorrhagia related to pure adenomyosis. Materials and Methods: This was a retrospective analysis of 14 patients with dysmenorrhea and menorrhagia related to pure adenomyosis treated with UAE using polyvinyl alcohol (PVA) between January 2017 and September 2019. The baseline and 3-month and 12-month postintervention outcomes were assessed using Uterine Fibroid Symptom-Health-Related Quality of Life Questionnaire (UFS-QOL), Symptom Severity Score (SSS), and magnetic resonance imaging findings. The median age of the patients was 47 years (28–55). The main clinical presentation was dysmenorrhea and menorrhagia, with a median duration of symptom of 24 (12–84) months. All patients received combined estrogen-progestin and nonsteroidal anti-inflammatory drugs prior to UAE without clinical improvement. Results: According to UFS-QOL and SSS results, the score for distress level was statistically significantly reduced from baseline 4.6 (3.6–5) to 2.25 (1–3.37) (P = 0. 018) after 3 months, and remained stable 12 months later. The score of symptom level was statistically significantly reduced from 4 (3.6–5) at baseline to 1.6 (1–3.58) (P = 0. 018) after 3 months with maintained clinical satisfaction after 12-month follow-up. The junctional zone was statistically significantly reduced from baseline with a median of 33.5 mm (19–79 mm) to 25 mm (8–77 mm) after 3 and 12 months (P = 0.046). The incidence of post-UAE permanent amenorrhea is 71% with a mean age of 49 years. No patient underwent hysterectomy during the follow-up period. Conclusion: UAE using PVA can improve the quality of life in patients with menorrhagia and dysmenorrhea related to adenomyosis. However, larger prospective studies are needed to establish the long-term outcomes and risk of amenorrhea. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|